THE ARTICLE by Bunney et al1 is a partial report of the efficacy and safety of triazolam (Halcion; Upjohn Co, Kalamazoo, Mich) for use as a sedative and hypnotic medication. The report was requested by the Food and Drug Administration (FDA) task force to provide an independent assessment of the safety and efficacy of this compound. The 7 recommendations of this report suggest the need for more data, better integration of clinical trial and postmarketing surveillance data, increased attention to long-term clinical trials, and development of methods to assess long-term effects, in terms of efficacy, tolerance, and safety.
Dunner DL. Long-term Use of Sedative and Hypnotic Medication. Arch Gen Psychiatry. 1999;56(4):355. doi:10.1001/archpsyc.56.4.355
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.